People with diabetes regularly receiving metformin in the relevant year

Description

This indicator shows the number and percent of people with diabetes receiving metformin regularly. Regular use was defined as metformin dispensed in three or more quarters in a year. 

Rationale

Analysing variation in metformin usage can offer insights into several aspects of diabetes management, including health care access and quality, provider practice, patient preferences, health literacy, adherence and tolerability. This information is valuable for designing targeted interventions to improve diabetes care and reduce disparities in health care delivery.  Metformin is commonly prescribed medicine for type 2 diabetes. Low metformin usage is a significant concern that warrants further investigation to identify the underlying contributing factors.

 

Measure set
Health areas and conditions
Notes about this measure set

Notes:

  • Metformin is also used to treat polycystic ovary syndrome in women aged 12‒45 years. Women within this age group, dispensed metformin, have not been included within the VDR unless they also have diabetes.

  • It was not possible to analyse indicator by the type of diabetes. However it is assumed that type 2 diabetes is more prevalent in people aged 25 years or over than type 1 diabetes.

Measure type
Count
Percent
Numerator

People with diabetes dispensed metformin in three or four quarters in the relevant year.

Numerator detail

Medications: 179401 & 179402 metformin hydrochloride

410426 vildagliptin with metformin hydrochloride

413825, 413826, 413827 and 413828 empagliflozin with metformin hydrochloride

Denominator

Count of distinct master NHIs identified as having diabetes as per the VDR.

Disaggregation

For single map analysis: By year (2018‒22), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other) and Health New Zealand district of domicile. 

For PHO analysis: By year (2022), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other), PHO most recently enrolled with (for the relevant year), PHO group (small, medium, medium‒large and large).

Notes

Exclusions 

  • People who died during the year
  • People not enrolled in a PHO

See technical document for details

Measure methodology last updated
June 2024
Reference period
2018-2022